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A B S T R A C T
Background
Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal
elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and
cardiovascular disease. Recent genome-wide association scans have found common genetic
variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9 gene
encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed
in the proximal nephron, a key site for urate handling in the kidney. We investigated whether
SLC2A9 is a functional urate transporter that contributes to the longstanding association
between urate and blood pressure in man.
Methods and Findings
We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms
mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200–500
lM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose
or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45-
to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is
facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the
uricosuric benzbromarone in a dose-dependent manner (Ki ¼ 27 lM). Furthermore, we found
urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing
SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due
to SLC2A9, and not another urate transporter, we showed that urate transport was diminished
by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that
genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with
common variation at SLC2A9 leading to increased serum urate. We found no evidence of
association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p. 0.33)
by meta-analysis of an SLC2A9 variant in six case–control studies including 11,897 participants. In
a separate meta-analysis of four population studies including 11,629 participants we found no
association of SLC2A9 with systolic (effect size0.12 mm Hg, 95% CI0.68 to 0.43, p¼ 0.664) or
diastolic blood pressure (effect size0.03 mm Hg, 95% CI0.39 to 0.31, p¼ 0.82).
Conclusions
This study provides evidence that SLC2A9 splice variants act as high-capacity urate
transporters and is one of the first functional characterisations of findings from genome-wide
association scans. We did not find an association of the SLC2A9 gene with blood pressure in this
study. Our findings suggest potential pathogenic mechanisms that could offer a new drug
target for gout.
The Editors’ Summary of this article follows the references.
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Introduction
Elevated serum urate levels are associated with important
common disorders such as gout, metabolic syndrome,
diabetes, hypertension, and cardiovascular morbidity and
mortality [1–4]. Uric acid is principally derived from the
breakdown of dietary and cellular purines. Humans and great
apes are exposed to higher urate levels than other mamma-
lian species because of the inactivation of hepatic uricase [5].
In humans the kidney has a pivotal role in urate handling,
with secretory mechanisms balanced against efﬁcient reab-
sorption resulting in only 10% of the ﬁltered load actually
being excreted in the urine [5]. The established urate
transporter systems in the proximal nephron includes; the
urate anion transporter (URAT1), which is a target of
uricosuric drugs, multiple organic anion transporters (OATs
1–4), the urate transporter (UAT), and a voltage dependent
organic anion transporter (OATv1) [5].
It is possible that genetic variation in either enzymatic
breakdown of purines or renal transporters of uric acid might
elevate serum levels and account for the long-standing
association with blood pressure and common cardiovascular
phenotypes [1–5]. Recently, two separate genome-wide asso-
ciation scans identiﬁed and replicated association of serum
urate level with common variants within the glucose trans-
porter SLC2A9 (GLUT9) gene region on Chromosome 4 [6,7].
Interestingly, this member of the facilitative glucose trans-
porter family has two splice variants most strongly expressed
in the apical and basolateral membranes of the proximal
tubular epithelial cells of the kidney [8,9]. SLC2A9 is not as
efﬁcient a glucose transporter as GLUT1 and GLUT4 [8], so we
set out to test whether SLC2A9a and SLC2A9b splice variants
act as urate transporters. We used data from the Olivetti Heart
Study to test association of SLC2A9 variants and fractional
urate excretion, and then tested for association with blood
pressure and hypertension in additional cohorts.
Methods
Reagents and Antibodies
All chemicals were obtained from Sigma-Aldrich unless
otherwise noted. Two polyclonal antibodies against N-
terminal peptides of both splice variants of human SLC2A9
were raised in rabbits (Rockland Immunochemicals). The
SLC2A9a antibody was raised against DTSHARPPGPGRAL-
LEC and the SLC2A9b was raised against KSRGEDEESD-
SAKKC. Both antibodies were peptide puriﬁed before use.
Two polyclonal antibodies against N-terminal peptides of
both splice variants of mouse SLC2A9 were also raised in
rabbits (Rockland Immunochemicals). The mSLC2A9a anti-
body was raised against MDSRELALASLMC and the
mSLC2A9b antibody was raised against MKLSEKNSAET-
KESC, and both antibodies were peptide puriﬁed before use.
mRNA Preparation and Xenopus laevis Oocyte
Microinjection
Plasmids containing genes encoding the wild-type human
SLC2A9a or SLC2A9b isoform were linearized with Nhe I and
transcribed in vitro with T7 polymerase mMESSAGE mMA-
CHINE (Ambion). Adult female X. laevis oocytes (prepared as
described in [9]) were injected with 20 nl (1 ng/nl) SLC2A9a or
SLC2A9b synthetic mRNA transcript and incubated for 5 d at
16–18 8C prior to functional uptake assays. The concentration
of RNA prior to injection was determined using Bio-Rad
SmartSpec 3000 machine.
Determination of Functional Activity by Radiotracer Flux
Assays
The inﬂux experiments were performed at 22 8C using 10–
12 oocytes for each condition and 14C-labelled urate at a
speciﬁc activity of 54 mCi/mmole, 250 lCi/ml. Oocytes were
washed with ice-cold modiﬁed Barth’s medium (MBM) to stop
the uptake, and then individual oocytes were placed in vials
and dissolved in 0.5 ml of 5% SDS for 30 min. Finally,
scintillation ﬂuid (5 ml) was added to each vial and radio-
activity measured using a Beckman LS6500 liquid scintillation
counter. All experiments were performed three to six times
and the results were corrected for the ﬂux values obtained
with non-injected oocytes obtained from the same frog.
Efﬂux experiments were performed by injecting oocytes
with 40 nl of 14C-urate just prior to the ﬂux measurements.
Eggs were then incubated in batches of 20 in 1 ml of medium
for 20 min at 22 8C. Samples of 20 ll of incubation medium
were taken every 2 min to measure the appearance of urate in
the outside solution. The incubation volume was kept
constant by sequential addition of medium after the removal
of each sample. The activity remaining in the eggs at the end
of the incubation was measured by solubilising the oocytes in
1 ml of 5% SDS overnight. Incubation medium consisted of
MBM supplemented with 5 mM D-glucose, D-fructose, uric
acid, or L-glucose (control). Efﬂux data were then plotted as a
function of the fraction of total urate remaining in the eggs at
each incubation time point. This was expressed as the log
(remaining urate/initial injected urate 3 100) for the
SLC2A9a-expressing eggs. Net SLC2A9a-mediated efﬂux was
determined by subtracting urate efﬂux observed in non-
injected oocytes from total urate efﬂux from SLC2A9a
oocytes at each time point.
Thin-Layer Chromatography
To determine if urate was metabolized within the Xenopus
oocytes we microinjected 40 nl of 14C- labelled 2 mM urate
and collected the efﬂux medium from both water-injected
eggs and those expressing SLC2A9a. We then loaded 100 ll of
the efﬂux media onto a silica-coated glass chromatography
plate and eluted with a 80:15:5 n-propanol:ammonium
hydroxide (25%):water solution. Standard urate and allantoin
solutions were used for comparison. After drying the plate, a
vanillin spray was used to visualize the urate and allantoin.
The Rf value (distance travelled from solvent front) for urate
was 0.0103 and that for allantoin 0.238.
Kinetic Analysis
Urate transport into oocytes expressing SLC2A9a or
SLC2A9b was measured over a range of concentrations from
0.001 to 2 mM using 20 min incubations, which had been
determined to be within the linear component of uptake.
Uptake was corrected for nonspeciﬁc entry using non-mRNA
injected eggs from the same batch in each experiment.
SIGMAPLOT 6 software was used to determine the transport
kinetics for the SLC2A9 mediated urate uptake by nonlinear
regression analysis. The analysis assumed standard simple
Michaelis-Menten kinetics for a facilitative transporter with
no cooperativity. In addition to the regression analysis, an
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Eadie-Hofstee linear transformation was included, the results
of which could imply that a more complex kinetic model is
required to fully describe the characteristics of this trans-
porter. Inhibitors were used at concentrations similar to
previous studies of other glucose or urate transporters, e.g.,
phloretin, benzbromarone, and furosemide, and which
corresponded with effective pharmacological doses, e.g.,
probenecid [10].
HEK293 Cells and Urate Uptake
HEK293 cells were stably transfected with human SLC2A9a
or SLC2A9b as shown previously [8]. These cells were grown to
90% conﬂuency in T75 ﬂasks. The cells were then washed with
EDTA, trypsinised, decanted into 15 ml conical tubes, and
centrifuged for 4 min at 1,100 rpm at 4 8C. The supernatant
was removed and the cells resuspended in 4 ml of Dulbecco’s
modiﬁed Eagle medium (DMEM) with 2% serum. After
incubation for 2 h at 37 8C while shaking at 120 rpm, the
cells were centrifuged for 4 min at 1,100 rpm at 4 8C and the
supernatant removed. Next, the cells were washed twice in
Kreb’s Ringer phosphate (KRP) buffer, centrifuged for 4 min
at 1,100 rpm at 4 8C and resuspended in 0.450ml of KRP buffer
with 50 ll of 1.2 mM 14C-labeled urate (Moravek Biochem-
icals). The cells were then incubated at 37 8C with shaking at
120 RPM for 6 min, after which they were placed on ice for 5
min. Finally, the supernatant was removed after centrifuga-
tion and the pellet washed twice with cold KRP buffer, before
lysis. After incubation in lysis media for 30 min on ice, a ﬁnal
centrifugation step at 1,100 rpm for 1 min was performed, a
500 ll aliquot of the supernatant was added to scintillation
ﬂuid (5 ml) and the radioactivity measured using a Beckman
LS6500 liquid scintillation counter. The remainder of the
supernatant was used for protein quantitation and Western
immunoblot. All experiments were done at least three times.
Western Immunoblot Analysis
Cell lysates were solubilised in Laemmli buffer and
subjected to SDS-PAGE, transferred onto nitrocellulose
membranes, blocked with 5% dry milk in Tris-buffered
saline/Tween 20 (TBS-T), and probed with an antibody raised
against the human SLC2A9a N terminus (1.5 lg/ml in 1% dry
milk/TBS-T), or the human SLC2A9b N terminus (1.0 lg/ml in
1% dry milk/TBS-T). For the murine insulinoma cell (MIN6)
lysates, polyclonal antibodies to the mouse SLC2A9a and
SLC2A9b, previously described, were used [11]. Blots were
then probed with a horseradish peroxidase-coupled goat
anti-rabbit secondary antibody (Santa Cruz Biotechnology)
and detection was performed using the SuperSignal Dura
Western kit (Pierce Biotechnology). Blot quantitation after
scanning was carried out using NIH Image.
Culture of Mouse Insulinoma Cells (MIN6)
MIN6 [12] cells were maintained in DMEM containing 25
mM glucose, supplemented with 15% heat-inactivated foetal
bovine serum, 50 lM b-mercaptoethanol, 100 U/ml penicil-
lin,100 lg/ml streptomycin, 100 lg/ml L-glutamine, 10 mM
HEPES, and 1 mM sodium pyruvate, in 5% CO2, 95% air at 37
8C. MIN6 cells were used between passages 20 and 30. The
radiolabelled urate uptake assays were conducted as described
above for the HEK293 cells. For the cold urate competition
assays, 50 ll of cold uric acid stock at a concentration of 1 mM
dissolved in Tris buffer (pH 8.1) was added to the KRP buffer
with labelled urate to give a ﬁnal concentration of 1 mM
unlabeled urate. The remainder of the assay was performed as
described above.
SLC2A9 siRNA Transfection
The polyamine transfection reagent, Trans IT- TKO
(Mirus) was used to transfect the insulinoma cells according
to the manufacturer’s instructions. The mouse SLC2A9 siRNA
and scrambled siRNA (negative control) were obtained from
Ambion. Cells were transfected for 72 h for protein isolation.
Radiolabelled urate uptake assays were conducted as
described above.
Association Studies with Serum Urate, Fractional Urate
Excretion, Blood Pressure, and Hypertension: Participants
The Olivetti Heart Study. The Olivetti Heart Study
population is derived from the male work force of the
Olivetti factories of Pozzuoli (Naples) and Marcianise (Case-
rta), Italy. The general characteristics of the study and its
methodological procedures have been described [12,13]. The
local ethics committee approved the study protocol, and
informed consent was obtained from all participants. A total
of 1,085 individuals aged 25–74 y were examined in 1994–
1995: of these, 907 (83.6%) were seen again in 2002–2004, and
of these, 868 individuals had DNA available for genotyping at
both time points [14]. We analysed individuals at both time
points for association with serum urate and fractional
excretion of uric acid and the 1994–1995 dataset only for
association with blood pressure and hypertension.
Whitehall II study. After ethical clearance the Whitehall
study enrolled 10,308 subjects (3,413 women) aged 35–55 y
working in the London ofﬁces of 20 civil service departments
between 1985–1988. In this longitudinal study, blood pressure
was recorded at phase 1 (1985–1988), phase 3 (1991–1993),
phase 5 (1997–1999), and phase 7 (2003–2004). DNA was
stored from phase 7 of the study. For association testing with
blood pressure and hypertension we selected individuals
from phase 5 as diabetes ascertainment and blood pressure
medication records were most complete from this phase. For
case–control analyses, hypertensive participants were se-
lected using the following criteria: blood pressure recordings
of  145/95 mm Hg, prescribed antihypertensive medication,
or a physician diagnosis of hypertension. Normotensive
control participants were selected on the basis of blood
pressure recordings  130/85 mmHg and not taking any
antihypertensive medications.
English Longitudinal Study of Ageing (ELSA). After ethical
approval the participants were drawn from around 12,000
respondents to the Health Survey for England (HSE) over
three separate years (1998, 1999, and 2001) to provide a
representative sample of the English population aged 50 y
and over. Each individual had a mean of three blood pressure
measures taken when the participant was seated, and
antihypertensive medications were recorded, DNA was
extracted from 5,672 participants in wave 2 (2004). For
association testing with blood pressure and hypertension we
selected individuals from wave 2. Cases and normotensive
controls were deﬁned using the same criteria as the Whitehall
II study.
BRIGHT study. The MRC BRIGHT study (http://www.
brightstudy.ac.uk/) comprises 2,500 hypertensive participants
and 2,000 normotensive controls of white European ancestry.
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Case ascertainment and phenotyping has been described
previously [15]. Brieﬂy, cases were included if they had blood
pressure readings  150/100 mm Hg based on one reading or
 145/95 mm Hg based on the mean of three readings.
Healthy age- and sex-matched normotensive controls (, 140/
90 mm Hg) were recruited using the same strict selection
criteria. Ethics Committee approval was received from the
multi- and local-research committees, and all participants
gave informed written consent.
London Life Sciences Prospective Cohort Study. The
London Life Sciences Prospective Cohort Study (LOLIPOP)
is a prospective study of potentially up to 24,000 participants
(UK-based individuals of Indian and white European ancestry)
recruited primarily for investigating cardiovascular risk
factors. For this study we selected white European individu-
als—485 hypertensive cases and 458 normotensive controls—
drawn from the top and bottom 10% of the blood pressure
distribution. All blood pressure readings were off-medication.
The Estonian HYPEST sample collection. The Estonian
participants were recruited during 2004–2007 across the
entire country in the framework of the HYPEST sample
collection (n ¼ 1,823) targeting hypertension risk factors in
the Estonian population (permissions no 122/13, 22.12.2003;
137/20, 25.04.2005 by Ethics Committee on Human Research
of University of Tartu, Estonia). Hypertensive patients were
recruited at the North Estonia Medical Center, Tartu Estonia.
Healthy (exclusion criteria: cardiovascular disease, diabetes,
and antihypertensive treatment), normotensive individuals
were recruited across the whole country. The majority of the
HYPEST participants (n ¼ 1,482) possess a documented
history of multiple systolic blood pressure (SBP) and diastolic
blood pressure (DBP) readings. For this study we deﬁned
cases (n ¼ 596) as individuals with either blood pressure
readings  160/100 mm Hg based on the median of several
measurements or under antihypertensive therapy. Controls (n
¼650) were deﬁned as having median blood pressure readings
below 140/90 mm Hg. The quantitative association analysis of
SBP and DBP (n ¼ 1,284) included both untreated (n ¼ 881)
and treated individuals (n ¼ 403).
Genotyping
Two variants of SLC2A9 (SNPs rs7442295 and rs13113918)
were investigated in the Olivetti Study for association with
serum urate and fractional urinary urate excretion. For
association analyses with blood pressure and hypertension,
one intragenic SNP (rs13113918)was genotyped in each cohort.
SNP genotyping in Olivetti, Whitehall II, and ELSA partic-
ipants was performed with TaqMan assay (Applied Biosystems)
followedby allelicdiscriminationusing theABIPRISM7900HT
Sequence Detection System and software (SDSv2.0, Applied
Biosystems) [16]. SNP genotyping in BRIGHT, HYPEST, and
LOLIPOP subjects was performedusing theKASPar chemistry,
a competitive allele-speciﬁc PCR SNP genotyping system using
FRET quencher cassette oligonucleotides [17]. SNPs were
checked for departure from Hardy-Weinberg equilibrium,
low minor allele frequency (,1%), and high level of missing
data. Allele frequencies at both sites were similar to those
previously reported in Hapmap [18].
Statistical Analysis
For the Olivetti study, between-group comparisons were
performed using unpaired t-tests for serum urate and
fractional uric acid excretion. Analysis of covariance was
used to model age and body mass index (BMI) covariation.
In order to test for associations with SNP rs13113918 we
performed linear regression for the quantitative phenotypes
(SBP and DBP) in Olivetti, Whitehall II, ELSA, and HYPEST
reported as effect size in mm Hg with 95% conﬁdence
intervals. We used logistic regression for the qualitative
phenotype hypertension (HYP) in all the studies reported as
an odds ratio with 95% conﬁdence intervals. Age, gender, and
BMI were included as covariates in all models. We tested
additive models of inheritance using either PLINK software
[19] or SAS v9.1. For individuals on antihypertensive
medication, we adjusted systolic and diastolic blood pressure
measures by adding 15 mm Hg to systolic and 10 mm Hg to
diastolic readings [20]. Individuals with BMI . 35 and those
with diabetes were excluded from all analyses.
Inverse-variance weighted meta-analysis was performed
using the ‘‘metan’’ [21] procedure in Stata 10.0.
Results
Human SLC2A9 Is a High-Capacity Urate Transporter
To test whether SLC2A9 splice variants act as urate trans-
porters we separately microinjected synthetic human
SLC2A9a and SLC2A9b mRNA transcripts into X. laevis
oocytes and measured uptake or efﬂux of radiolabelled urate.
Both proteins were readily expressed in the oocyte plasma
membrane within a couple of days as conﬁrmed by immuno-
histochemistry (Figure S1). However, we studied the oocytes 4
d after mRNA injection so that urate ﬂuxes could be
determined under the same conditions as previously published
for SLC2A9 mediated hexose transport. We found that human
SLC2A9a and SLC2A9bmediated very rapid urate ﬂuxes which
necessitated incubation for only 20 min in subsequent kinetic
and inhibition experiments (Figure 1A). In contrast, uptake of
urate into non-injected eggs was very slow, indicating
negligible endogenous transport activity for this substrate.
Transport was then measured over a range of urate concen-
trations, which bracketed the normal human physiological
plasma concentrations (200–500 lM). Both human SLC2A9a-
and SLC2A9b-mediated urate ﬂuxes showed saturation and
were identical, so data for the two splice variants were
combined for kinetic analysis. Figure 1B shows the averaged
data from six such experiments and nonlinear regression
analysis was used to ﬁt a Michaelis-Menten function with a Km
of 981 lM and a Vmax of 304 pmol/oocyte/20 min. The insert
shows the Eadie-Hofstee plot for the same data. In contrast, we
were unable to detect any urate ﬂux (100 lM) mediated by
either human GLUT1 (SLC2A1) or GLUT2 (SLC2A2), both
class I facilitative glucose transporters (Figure 1C).
Transport of Urate by SLC2A9 Shows Limited Sensitivity to
Uricosurics
A number of compounds known to promote urate loss in
the urine via inhibition of other renal urate transporters such
as URAT1 were tested to determine if they reduced SLC2A9
mediated urate transport. Benzbromarone showed a dose-
responsive inhibition with 10 lM reducing urate uptake by
34% and 100 lM by 80% (Figure 1D). Additional kinetic
analyses using two concentrations of urate (10 and 100 lM)
and a Dixon analysis showed that the Ki for benzbromarone
inhibition of urate transport mediated by SLC2A9a was 27
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Figure 1. Characterisation of Urate Fluxes and Kinetics Mediated by Human SLC2A9 Expressed in Xenopus laevis Oocytes and the Effect of Short-Chain
Fatty Acids and Uricosurics on Urate Transport
(A) Time course of SLC2A9a-mediated urate uptake into Xenopus oocytes. Oocytes were injected with SLC2A9a cRNA or water and 4 d later incubated
with 10 lM urate at 22 8C for the time periods indicated. Symbols represent the average uptake into ten oocytes per time point, with error bars
representing the standard error of the mean (SEM). Solid circles show total uptake into oocytes expressing SLC2A9a cRNA, open circles urate uptake into
water-injected oocytes, and inverted triangles the net uptake obtained by subtracting the water data from the total uptake for each time point.
(B) Kinetics of human SLC2A9-mediated urate uptake in Xenopus oocytes. Symbols represent the mean data from six separate experiments each using
ten oocytes per substrate concentration. Uptake was measured in oocytes injected with either SLC2A9a or SLC2A9b cRNA 4 d prior and corrected for
uptake into water-injected oocytes. The curve was fitted by nonlinear regression analysis. The Km¼ 981 lM and the Vmax¼ 304 pmol/oocyte/20 min.
Insert shows an Eadie-Hofstee plot of the same data.
(C) Effect of uricosemics and short chain fatty acids on human SLC2A9a mediated urate uptake. Xenopus oocytes were injected with water or SLC2A9a
cRNA and urate uptake measured 4 d later. Oocytes were incubated with 10 lM urate for 20 min, and bars represent net uptake determined by
subtracting uptake into water-injected eggs from total uptake into SLC2A9a expressing oocytes, error bars are the SEM. Note: at no time was the urate
uptake into the water-injected eggs more than 11% of the total uptake into SLC2A9-expressing oocytes. Compounds used were: no additional reagent
(Cont), lactate 1 mM (Lac), pyruvate 1 mM (Pyr), butyrate 1 mM (But), acetate 1 mM (Ace), probenecid 1 mM (Prob), furosemide 100 lM (Furo), and
phloretin 1 mM (Phlo). For comparison, a separate series of oocytes were injected with SLC2A1 (GLUT1) or SLC2A2 (GLUT2) cRNA and 100 lM urate
uptake measured 4 d later using 30 min incubation times. Bars represent net uptake corrected for uptake into water-injected oocytes. *Significant
inhibition at p  0.05.
(D) Dose-dependent effect of benzbromarone on SLC2A9a-mediated urate uptake. Oocytes were injected with SLC2A9a cRNA or water and 4 d later
were incubated with 10 lM urate for 20 min in the presence of 0, 1, 10, or 100 lM benzbromarone. Points represent the mean net uptake into ten
oocytes corrected for uptake into water-injected eggs. Error bars were smaller than the data points.
doi:10.1371/journal.pmed.0050197.g001
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lM. However, probenecid at a concentration of 1 mM had no
signiﬁcant effect on urate uptake, p . 0.05 (Figure 1C).
Similarly, furosemide had no signiﬁcant effect at 100 lM, and,
of the short chain fatty acids lactate, pyruvate, butyrate, and
acetate at a concentration of 1 mM, only lactate induced a
small and just signiﬁcant inhibition, p , 0.05 (Figure 1C).
Finally, the class I hexose transporter inhibitor phloretin had
no signiﬁcant effect on urate transport (, 10% inhibition)
when applied at a concentration of 1 mM, p. 0.05 (Figure 1C).
SLC2A9 Mediates Exchange of Urate for Glucose or
Fructose
Because SLC2A9a and SLC2A9b have previously been
characterized as high-afﬁnity, low-capacity glucose and
fructose transporters, we tested the ability of these two
hexoses to inhibit urate ﬂuxes and, conversely, for urate to
inhibit hexose uptake. Surprisingly, concentrations of glucose
up to 1 mM had no effect on the transport of 10 lM urate
(Figure 2B), and urate concentrations of up to 2 mM had no
effect on the uptake of 50 lM D-glucose or D-fructose (Figure
2A and 2C). Note that the rates of urate transport were
signiﬁcantly greater than those for glucose. Urate ﬂuxes were
measured at 5 or 10 lM for only 20 min, whereas glucose rates
were determined using 50 lM substrate for 30 min. Thus,
converting ﬂux rates to the same time period and equivalent
concentrations suggest that urate is transported by SLC2A9
at rates 45- to 60-fold faster. The lack of signiﬁcant
competition between the hexoses and urate suggests that
urate binds to a site on SLC2A9 that is different from the
binding site for the hexoses. However, it could be argued that
the injection of SLC2A9 mRNA was inducing expression of
an endogenous protein that could separately mediate urate
uptake. Therefore, we attempted to determine whether
SLC2A9 could exchange hexoses with urate, providing
further support for a single pathway mechanism. Since
glucose and fructose are both rapidly phosphorylated upon
entry into the oocyte, only urate efﬂux could be used to give a
meaningful estimate of exchange rates. Oocytes were injected
with radiolabelled urate and the efﬂux determined in the
presence of 5 mM extracellular D-glucose, D-fructose, L-
glucose, or 2 mM urate. Urate efﬂux could be described by a
single exponential curve over a period of up to 20 min, and
the presence of extracellular D-glucose greatly accelerated
urate movement, while fructose did so to a lesser degree (7-
fold versus 3-fold, respectively, Figures 3A and 3B). Extrac-
ellular cold urate accelerated the efﬂux of radiolabelled urate
to the greatest degree, while extracellular L-glucose had no
effect. Thin-layer chromatography was used to analyze the
efﬂux medium, and only urate and no allantoin were detected
on the plate for both water-injected eggs and those
expressing SCL2A9a. Thus, SLC2A9 exhibits classical ex-
change trans-stimulation between urate and glucose or
fructose. The rate of loss of injected radiolabelled L-glucose
into the efﬂux medium was negligible, indicating that the
injection protocol did not result in a nonspeciﬁc leakage of
the substrate from the oocytes (Figure 3A).
The exchange of urate for glucose was conﬁrmed by
preloading the oocytes with 2 mM cold urate for 1 h and then,
after washing, to remove extracellular urate, measuring the
uptake of 100 lM D-glucose. The inﬂux of D-glucose was
increased 3-fold by intracellular urate in SLC2A9a-expressing
eggs compared to preincubation with 2 mM L-glucose (Figure
2D). These data conﬁrm that SLC2A9a can exchange
extracellular glucose for intracellular urate.
Increased Urate Uptake by Kidney Cells Overexpressing
SLC2A9 Isoforms
Both overexpressed proteins appear as a smear of
glycosylated bands between 37 and 50 kDa, as previously
reported using a different polyclonal antibody to the C
terminus that was unable to distinguish SLC2A9a from
SLC2A9b [8,21]. Previous studies had also already demon-
strated plasma membrane expression of human (h) SLC2A9
in these cell lines [8]. In order to check the speciﬁcity of each
antibody, total protein from cells overexpressing the differ-
ent splice variants were loaded side by side in polyacrylamide
gels and immunoblotted with the two antibodies separately.
Each individual antibody detected the correct overexpressed
protein but not the alternative splice variants. Both SLC2A9a
and SLC2A9b were expressed at low levels endogenously in
HEK293 cells as seen by the multiple bands in lanes 1 and 3 of
Figure 4A and lanes 1 and 2 of Figure 4B. In prior studies we
have demonstrated that these multiple bands in HEK cells
reduce to one band at 37 kDa upon deglycosylation [8]. In the
presence of preimmune sera (unpublished data) no speciﬁc
bands were detected.
We observed that radiolabelled uric acid was transported
into the HEK293 cells stably overexpressing either human
SLC2A9a or SLC2A9b at the cell surface. The rate of urate
uptake was at least 2-fold greater than for control HEK293
cells (Figure 4C).
Confirmation of SLC2A9-Mediated Urate Transport in a
Second Mammalian Cell Line
In order to verify the ﬁndings in kidney cells, we used a
mouse insulinoma cell line (MIN6 cells) endogenously
expressing detectable levels of both murine SLC2A9a and
SLC2A9b protein. We veriﬁed the expression of both mouse
SLC2A9a and SLC2A9b protein by using antibodies speciﬁ-
cally raised against the N termini of each murine isoform
(Figure 5A). We have previously reported SLC2A9 expression
in MIN6 cells and islets from both human and mouse [11]. The
speciﬁcity of these antibodies has been previously reported
[11,22]. Mouse SLC2A9a and SLC2A9b in MIN6 cells appear as
a doublet with the isoform-speciﬁc antibodies as previously
shown in both cell lines as well as mouse and ovine tissues [22–
24]. The molecular weights are consistent with that published
previously for these isoforms in mouse tissue [11].
MIN6 cells take up radiolabelled urate at a rate of 6–7
pmoles/min/mg protein (Figure 5B). In order to test the
speciﬁcity of SLC2A9a and SLC2A9b for urate, non-radio-
labelled urate was added to the uptake assay at a ﬁnal
concentration of 1 mM. The cold urate signiﬁcantly inhibited
radiolabelled uptake by approximately 50% (Figure 5B).
These ﬁndings suggest that the SLC2A9 isoforms are speciﬁc
for urate.
Urate Uptake Is Inhibited by siRNA against SLC2A9 but
Not Scrambled RNA
As a ﬁnal check of the speciﬁcity of the SLC2A9 trans-
porter for urate, endogenous expression of mouse SLC2A9a
and SLC2A9b in MIN6 cells was knocked down by small
interfering RNAs (siRNAs) for both isoforms. Western
immunoblotting conﬁrmed a signiﬁcant decrease in SLC2A9a
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Figure 2. Interaction between Hexoses and Human SLC2A9a-Mediated Urate Uptake in Xenopus Oocytes
Oocytes were injected with SLC2A9a cRNA 4 d prior to uptake experiments. Symbols represent mean net substrate uptake and error bars the SEM for
measurements made in 6–10 oocytes per condition. Total uptake of substrates was measured into SLC2A9a cRNA-injected oocytes and then corrected
for the uptake measured under identical conditions using water injected oocytes from the same batch of eggs.
(A) Uptake over 30 min of 50 lM glucose in the presence of increasing concentrations of urate.
(B) Uptake over 20 min of 5 lM urate in the presence of increasing concentrations of glucose.
(C) Uptake over 30 min of 50 lM fructose in the presence of increasing concentrations of urate.
(D) Human SLC2A9a-mediated glucose and urate exchange. Oocytes injected with SLC2A9a cRNA or water, 4 d prior, were incubated with non-
radiolabelled 2 mM L-glucose or 2 mM urate for 1 h. Oocytes were then washed and then incubated at 22 8C for 30 min in 14C-labeled 10 lM D-glucose.
Bars represent the average total uptake into 20 eggs expressing SLC2A9a or water-injected eggs, and the difference between the two, the net uptake.
Error bars represent the SEM.
doi:10.1371/journal.pmed.0050197.g002
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and SLC2A9b expression in MIN6 cells (Figure 5C). As a
result, radiolabelled urate uptake was signiﬁcantly decreased
(Figure 5D) by approximately 50%. Expression and uptake
were unaffected by the scrambled RNA.
Association of SLC2A9 Gene Variants with Serum and
Fractional Excretion of Urate
The Olivetti Heart Study has previously shown strong
correlations between uric acid, urate tubular handling, and
blood pressure level [12]. We genotyped rs7442295, which had
demonstrated the strongest support for association with
urate in our previous study, and rs13113918, an intragenic
SNP in 868 individuals that had been surveyed at two time
points (1994–1995 and 2002–2004). After adjusting for age we
conﬁrmed association of both variants with serum uric acid
level and detected a complementary association of these
variants with reduced urate fractional excretion, which ﬁts
with common allelic variation reducing urate clearance by
the kidney (Table 1). These associations were evident at both
1994–1995 and 2002–2004 time- points, and after adjustment
for BMI and after exclusion of subjects on antihypertensive
therapy (unpublished data).
Association Studies of the SLC2A9 Gene with Blood
Pressure
For reporting our results here we focus upon the additive
model for all cohort analyses, because the association of
SLC2A9 SNPs with serum urate is best described by this model
[7]. We performed a quantitative genetic analysis of blood
pressure variation with an intragenic SNP rs13113918 in four
populations; demographic details for each are summarised in
Table 2. In Table 3 we show the analysis of each of these
cohorts and the global p-value from meta-analysis of systolic
and diastolic blood pressure. We found no association with
SBP (meta-analysis for SBP showed the effect size of the
SLC2A9 variant to be0.12 mm Hg, 95% CI0.68 to 0.44, p¼
0.66) or DBP (meta-analysis for DBP showed the effect size of
the SLC2A9 variant to be0.04 mm Hg, 95% CI0.39 to 0.31,
p¼0.82) within each population or in meta-analyses under an
additive model (Table 3).
Association Studies of the SLC2A9 Gene with
Hypertension
We analysed rs13113918 under additive model of inher-
itance within cases and controls from the BRIGHT study
(2,052 hypertensives and 1,637 normotensive controls), the
Estonian HYPEST study (596 hypertensives and 650 normo-
tensive controls), the LOLIPOP study (498 hypertensives and
498 normotensive controls), Olivetti 94 (182 hypertensives
and 549 normotensive controls), Whitehall II (961 hyper-
tensives and 2,365 normotensive controls) and ELSA (960
hypertensives and 949 normotensive controls) with demo-
graphics shown in Table 2. The results of our meta-analysis
combining six case–control studies (see Table 4) did not show
a signiﬁcant association between hypertension and the
Figure 3. Human SLC2A9a-Mediated Urate Efflux from Xenopus Oocytes
(A) Comparison of urate and L-glucose efflux from SLC2A9a-expressing oocytes. Oocytes injected with SLC2A9a cRNA 4 d prior (triangles) or water-
injected eggs (circles or squares) were injected with 14C-labelled urate (circles, triangles, or diamonds) or 14C-labelled L-glucose (filled squares) to give an
estimated initial intracellular concentration of 200 lM. 20 oocytes per condition were incubated at 22 8C in efflux medium, which was sampled every 2
min. Efflux media contained 5 mM D-glucose (open circles), 5 mM L-glucose (filled squares, circles or triangles), or 2 mM urate (filled diamonds). Data
points represent the log percentage of urate or L-glucose remaining in the oocytes for each time point. Lines were fitted by linear regression.
(B) Acceleration of SLC2A9a mediated urate efflux by extracellular D-glucose or D-fructose. Oocytes injected with SLC2A9a cRNA 4 d prior (triangles) or
water-injected eggs were injected with 14C-labelled urate to give an estimated intracellular concentration of 200 lM. 20 oocytes per condition were
incubated at 22 8C in efflux medium, which was sampled every 2 min. Efflux media contained 5 mM D-glucose (filled circles), 5 mM L-glucose (filled
triangles) or 5 mM D-fructose (open circles). Data points represent the log percentage of urate remaining in the oocytes for each time point corrected
for the efflux of urate from the water-injected eggs under the same conditions. Lines were fitted by linear regression.
doi:10.1371/journal.pmed.0050197.g003
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SLC2A9 variant tested (odds ratio 0.98, 95% CI 0.91 to 1.05, p
. 0.6).
Discussion
Recent genome-wide association scans identiﬁed and
replicated association between SNPs at the SLC2A9 gene
locus and serum urate and with gout [6,7,25,26]. In this study
we have shown that both human SLC2A9 splice variants,
SLC2A9a and SLC2A9b, can mediate urate ﬂuxes at a very
high rate and signiﬁcantly faster than their facilitated
transport of either glucose or fructose. The kinetics indicate
that the transporter’s apparent capacity for substrate, or Km
value (; 1 mM), is above the basal, physiologic plasma
concentrations of urate. Moreover, the Vmax value indicates a
high-capacity transporter. All of these data suggest that this
membrane protein plays an important role in the handling of
urate in the proximal nephron, which completely ﬁts with the
Figure 4. Specificity of Human SLC2A9a and SLC2A9b Antibodies and Urate Uptake into SLC2A9 Transfected Human Embryonic Kidney Cells
(A) Western blotting of hSLC2A9 expressed in HEK cells. Expression of hSLC2A9a was detected as a broad band at approximately 50 kDa by a polyclonal
antibody raised against the N terminus of SLC2A9a in HEK293 cells overexpressing SLC2A9a (middle lane, Slc2a9a) but not detected in cells
overexpressing SLC2A9b (right lane, Slc2a9b), or nontransfected HEK cells (left lane, HEK).
(B) Expression of hSLC2A9b in transfected HEK293 cells. hSLC2A9b was detected by a polyclonal antibody raised against the N terminus of hSLC2A9b in
HEK293 cells overexpressing hSLC2A9b (right lane, Slc2a9b), but not detected in cells overexpressing hSLC2A9a (middle lane, Slc2a9a).
(C) Increase in urate uptake in HEK293 cells overexpressing either hSLC2A9a or hSLC2A9b. Radiolabelled urate uptake was measured in human
embryonic kidney cells, which were stably overexpressing SLC2A9a or SLC2A9b as compared to their respective nontransfected controls. Uptakes of 120
lM urate were measured over 6 min at 37 8C. *p , 0.05; **p , 0.02.
doi:10.1371/journal.pmed.0050197.g004
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ﬁndings from genome-wide scans of common allelic variation
elevating urate by 20 lmol/l per allele [7]. In the context of
everyday clinical practice this genetic inﬂuence on urate is
equivalent to 5%–10% of the normal range of serum urate
(180 lmol/l to 420 lmol/l), which is not trivial. These ﬁndings
are conﬁrmed by complementary functional studies on
SLC2A9 in relation to urate handling and gout [25–27].
Current models of urate handling in the proximal
convoluted tubule indicate that several types of transporter
are involved in the ﬂuxes of urate across both the apical and
the basolateral membranes of the epithelial cells. In the apical
membrane, these transporters include URAT1, a urate/lactate
exchanger that mediates urate movement from urine to
epithelium [28]; OATv1, a putative voltage dependent organic
anion transporter [29]; MRP4, an ATP driven pump [30]; and
UAT, a postulated urate channel [31]. At the other pole of the
cells two of the organic anion exchangers, OAT1 and OAT2,
present in basolateral membrane, are thought to be able to
handle urate, but their physiological role remains to be
conﬁrmed [32,33]. Therefore at present there is a well-deﬁned
Figure 5. Expression of SLC2A9 and Urate Uptake into Mouse Insulinoma MIN6 Cells
(A) Western blotting of mouse SLC2A9 in MIN6 cells. Cell lysates were analyzed by Western blot using antibodies to murine SLC2A9a and SLC2A9b of
MIN6 cell lysates.
(B) 14C-urate uptake into MIN6 cells is competitively inhibited by cold urate. Radiolabelled urate uptake was measured in mouse insulinoma cells, which
endogenously express mSLC2A9a or mSLC2A9b. Uptake of 14C-urate, 120 lM, was measured for 6 min at 37 8C in the presence or absence of an
additional 1mM cold urate. ** p , 0.02.
(C) SLC2A9a and SLC2A9b expression is reduced by treatment of MIN6 cells with siRNA specific for mSLC2A9. Cells were treated with either scrambled
RNA (scRNA) or mSLC2A9-specific siRNA and cell lysates run on a Western blot and probed with an antibody specific for either mSLC2A9a (mGLUT9a) or
mSLC2A9b (mGLUT9b).
(D) Reduction of urate uptake into MIN6 cells by transfection with siRNA targeted to SLC2A9. MIN6 cells were transfected with either SLC2A9-specific
siRNA9 or scrambled RNA (scRNA). 14C-urate, 120 lM, uptake into transfected or untransfected cells was measured for 6 min at 37 8C. *p , 0.05.
doi:10.1371/journal.pmed.0050197.g005
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absorptive route across the apical membrane via UAT1 and a
secretory route via MRP4, while the means by which urate can
either leave the renal epithelium and enter the blood or move
in the opposite direction across the basolateral membrane
remains to be conﬁrmed.
Recently, it has been proposed that both SLC2A9 proteins
are high-afﬁnity glucose/fructose transporters. However,
when compared with the principal members of the SLC2A9
gene family their transport capacity (Vmax) is very low [11,34].
We now have evidence that urate is a preferred substrate for
both human SLC2A9 variants and for the mouse orthologue.
The ability of SLC2A9 to exchange urate with glucose in the
absence of competition between these two substrates when
present on the same side of the membrane indicates that the
protein has separate binding sites. This is not a unique
phenomenon in exchange proteins, as the glycerol-6-phos-
phate transporter exchanges glycerol-6-phosphate for inor-
ganic phosphate [35].
This ability of SLC2A9 to exchange glucose and, to a lesser
degree, fructose for urate may be physiologically important.
The renal proximal nephron plays a major role in the
reabsorption of glucose from the urine using a combination
of sodium-coupled hexose transporters, SGLT1 and SGLT2,
and members of the SLC2A family, GLUTs 2, 5, and possibly 9
[36–40]. Furthermore, the proximal convoluted tubular
epithelium is a major site of gluconeogenesis, converting
pyruvate to glucose, which is then released across the
basolateral membrane into the blood [41–43]. Our data
showing that SLC2A9a can exchange glucose for urate suggest
that this protein might play an important role in the
secretion of urate from the blood into the urine. Glucose in
the urine could exchange for urate in the proximal
convoluted tubule epithelial cells across the apical mem-
brane, resulting in the release of urate back into the urine. In
addition, glucose in the epithelial cells resulting both from
reabsorption and neogenesis could exchange for plasma
urate across the basolateral membrane, promoting the
accumulation of urate in the cells. Furthermore, such a
mechanism could explain the known correlation between the
glycosuria seen in diabetes and the reduction in plasma urate
levels. The increased glucose in the urine could accelerate the
SLC2A9-mediated urate efﬂux across the apical membrane of
the proximal convoluted tubule, but further work is needed
to conﬁrm this hypothesis.
Therefore, our ﬁndings, in combination with epidemio-
logic data showing correlation of elevated serum urate with
Table 1. Genetic Association Results for SNPs rs13113918 and rs7442295 in the Olivetti Heart Study in 1994–1995 and 2002–2004 with
Serum Uric Acid and Fractional Excretion of Urinary Urate
SNP Urate Variable Genotype n 1994–1995
Meana
p-Value n 2002–2004
Meana
p-Value
rs13113918 Serum uric acid (lmol/l) AA 43 293 1.6 3 107 44 264 5.5 3 106
AG 314 330 318 300
GG 500 351 506 309
Fractional excretion of uric acid (%) AA 42 9.6 0.007 44 9.9 2.7 3 107
AG 303 8.8 318 8.2
GG 479 8.1 502 7.8
rs7442295 Serum uric acid (lmol/l) AA 489 349 2.2 3 106 496 308 8.0 3 105
AG 320 330 324 300
GG 41 300 41 266
Fractional excretion of uric acid (%) AA 470 8.2 0.026 493 7.8 2.2 3 108
AG 308 8.6 323 8.1
GG 40 9.8 41 10.4
a This table shows increase in serum urate and reduced urinary fractional excretion in measurements of urate per allele for the two SNPs studied at two timepoints 8 y apart (1994 and
1995 and then between 2002 and 2004).
doi:10.1371/journal.pmed.0050197.t001
Table 2. Demographic Characteristics Per Cohort for Genetic Studies
Cohort Numbers Male/Female Age Mean (SD) BMI Mean (SD) SBP Mean (SD) DBP Mean (SD)
Olivetti 94 868 868 51.5 (7.0) 27 (3.0) 129.7 (16.9) 84 (9.7)
HYPEST 1,284 440/844 46.26(13.12) 26.13 (3.78) 137.1 (15.14) 84.9 (9.15)
WH2 4,867 3,620/1,247 55.42 (5.97) 26.04 (3.88) 122 (15.92) 77.1 (10.36)
ELSA 5,422 2,323/2,745 63.64 (9.45) 27.77 (4.69) 136.1 (18.77) 75.7 (10.96)
BRIGHTa 2,445/2,000 1,769/2,676 57(10.8)/58.8 (9.0) 27.4 (3.8)/25.3 (3.3) 154 (20.8)/123 (10.5) 94 (11.1)/76.5 (7.1)
LOLIPOPa 498/498 626/370 52 (11.3)/52 (11.2) 28 (3.7)/24 (3.3) 154.7 (17.9)/108 (9.8) 95 (7.8)/65 (5.6)
HYPESTa 596/650 397/849 48.77 (13.65) 26.45 (4.3) 144.2 (18)/128 (8.2) 87.6 (10.4)/80.6 (6.3)
aFor BRIGHT, LOLIPOP, and HYPEST cohorts, the numbers are expressed as cases/controls. Breakdown according to hypertensive cases and normotensive controls separately.
BRIGHT, British Genetics of Hypertension Study; ELSA, English Longitudinal Study of Ageing; HYPEST, Estonian Hypertension Cohort; LOLIPOP, London Life Sciences Prospective Cohort;
Olivetti 94, Olivetti Heart Study; WH2, Whitehall 2 Study.
doi:10.1371/journal.pmed.0050197.t002
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diabetes, metabolic syndrome, obesity, and hyperinsulinae-
mia, provide a potential mechanism for these associations
that warrants further investigation [44–46]. In this context it
is of particular interest that recent data from the Health and
Nutrition Survey shows correlation between consumption of
sugar-based soft drinks with serum urate levels and gout,
which might be partly explained by sugar-facilitated uptake
of urate by SLC2A9 isoforms [47].
Probenecid and benzbromarone are uricosuric drugs that
inhibit renal uptake of urate via URAT 1 on the apical
proximal nephron membrane [5]. We found that probenecid
had no effect on urate uptake into SLC2A9a-expressing
oocytes, whereas benzbromarone showed a dose-dependent
inhibition. The signiﬁcant inhibition of urate transport by 10
and 100 lM benzbromarone implies that there are common
features in the binding sites for urate in both URAT1 and
SLC2A9a. When in clinical use benzbromarone promoted the
loss of urate in the urine; this is believed to be a consequence
of an inhibition of uptake across the apical membrane
mediated by URAT1 [2]. In contrast, the high Ki of 27 lM for
benzbromarone action on SLC2A9 suggests that at therapeu-
tic doses this drug would have a minimal effect on urate
transport mediated by this protein and so does not affect
urate secretion.
The Olivetti Heart Study has previously found a strong
longitudinal relationship of serum urate levels with blood
pressure [48]. The authors also reported a correlation of
urate with reduced fractional clearance of lithium as an index
of sodium reabsorption in the proximal nephron. This
ﬁnding could reﬂect sodium retention and offer a mechanism
for previously reported associations of urate and blood
pressure [12]. The two SNPs genotyped in the Olivetti cohort
validate association of the SLC2A9 locus with serum urate and
demonstrate the association of both SNPs with reduced
urinary urate excretion at two time points 8 y apart. This
provides additional support for our hypothesis that SLC2A9
variants reduce urinary urate loss and is further conﬁrmed by
recent cross-sectional ﬁndings for this gene in gout [25–27].
In view of the additive inﬂuence of alleles of SLC2A9 on
serum uric acid and urinary urate excretion, we explored a
relationship between SLC2A9 SNPs with systolic and diastolic
blood pressure in 11,629 individuals under an additive model.
This analysis showed no signiﬁcant association between SNP
rs13113918 and blood pressure. Furthermore, we did not ﬁnd
any evaluated association of the same SLC2A9 SNP with
hypertension under an additive model in 5,249 hypertensive
cases and 6,648 normotensive controls drawn from all the
studies. In the context of this large-scale case–control and
population-based cohorts we conclude that there is no
support for an association with blood pressure using the
most biologically plausible genetic model.
Table 3. Association of SNPs rs13113918 with SBP and DBP under an Additive Genetic Model of Inheritance
Association Population n Effect, mm Hg 95% CI % Weight p-Value
SBP Whitehall II 4,682 0.434 1.269 to 0.40 45.19 0.31
ELSA 4,880 0.319 0.664 to 1.303 32.54 0.52
HYPEST 1,238 0.931 2.402 to 0.540 14.54 0.22
Olivetti 94 829 1.338 0.680 to 3.356 7.73 0.19
Meta-analyses — 0.124 0.685 to 0.437 100 0.664
DPB Whitehall II 4,682 0.125 0.680 to 0.430 40.37 0.66
ELSA 4,880 0.044 0.529 to 0.616 37.97 0.88
HYPEST 1,238 0.373 1.337 to 0.691 13.39 0.45
Olivetti 94 829 0.542 0.685 to 1.769 8.26 0.38
Meta-analyses — 0.039 0.392 to 0.314 100 0.829
The table shows the number in each cohort, the effect size of the SLC2A9 allele in mm Hg, 95% CI, percentage weight, and p-value by cohort and for the meta-analyses for SBP and DBP.
SBP meta heterogeneity, p¼ 0.214; DBP meta heterogeneity, p¼ 0.683.
doi:10.1371/journal.pmed.0050197.t003
Table 4. Results of SNP rs13113918 of SLC2A9 within Individual Hypertensive Case–Control Participants from All Resources and in
Meta-analysis Analysed under an Additive Model Testing for Influence on Hypertension
Population n (Cases/Controls) OR 95% CI % Weight p-Value
Whitehall II 961/2,365 0.840 0.773 to 0.963 27.05 0.01
ELSA 960/949 0.956 0.814 to 1.121 19.74 0.57
HYPEST 596/650 1.330 0.979 to 1.807 5.37 0.07
Olivetti 94 182/549 1.216 0.889 to 1.663 5.15 0.22
BRIGHT 2,052/1,637 1.048 0.930 to 1.181 35.47 0.44
LOLIPOP 498/498 0.925 0.710 to 1.205 7.23 0.56
Meta-analyses — 0.980 0.913 to 1.053 100 0.587
The Table shows the number (n) of cases and controls by study and for meta-analysis presented as the odds ratio for association with hypertension, the associated 95% CI, the percentage
weight, and p-value. Meta heterogeneity, p¼ 0.035.
OR, odds ratio.
doi:10.1371/journal.pmed.0050197.t004
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Limitations of This Study
We have not deﬁned precisely the causative variant of
SLC2A9 responsible for elevated serum urate and reduced
urinary urate clearance. There are several known SNPs within
the gene region that might inﬂuence function of the SLC2A9
protein. Such studies will be facilitated by detailed re-
sequencing of the SLC2A9 gene to establish a comprehensive
inventory of genetic variation across this locus. In addition to
dietary and metabolic inﬂuences on uric acid levels there will
be other, as-yet unidentiﬁed genetic inﬂuences on serum
urate level that may contribute to epidemiologic correlations
with metabolic syndrome, diabetes, gout, and cardiovascular
disease.
Conclusion
In this paper we have translated the genetic association of
the SLC2A9 locus with serum urate derived from genome-
wide scanning into a functional conﬁrmation that SLC2A9
splice variants acts as a high-capacity urate transporter that
can be facilitated by exchange with hexoses and inhibited by
high concentrations of some uricosurics and siRNA technol-
ogy. These ﬁndings offer novel potential pathogenic mech-
anisms and new drug targets for diseases such as gout.
Supporting Information
Figure S1. Expression of SLC2A9a or 9b in Xenopus Oocyte Plasma
Membrane after cRNA Injection
Oocytes were injected with 50 nl (1 ng/nl) SLC2A9a or SLC2A9b
cRNA or water and incubated at 18 8C for 4 d. The expression of
SLC2A9a and SLC2A9b was visualized using a primary antibody to
the same C-terminal peptide sequence of both proteins, a ﬂuorescent
secondary antibody, and confocal microscopy. All three images show
the x, y, and z within the same focal plane.
(A) Water-injected oocyte.
(B) SLC2A9a.
(C) SLC2A9b.
Found at doi:10.1371/journal.pmed.0050197.sg001 (204 KB PDF).
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Editors’ Summary
Background. Blood is continually pumped around the human body to
deliver the chemicals needed to keep the body’s cells alive and to take
cellular waste products to the kidneys where they are filtered out of the
blood and excreted in the urine. In healthy people, the levels of nutrients
and waste products in serum (the liquid part of blood) fall within
‘‘normal’’ ranges but in ill people these levels can be very different. For
example, serum uric acid (urate) levels are usually increased in people
with gout. In this arthritic condition, uric acid crystallizes in the joints
(often those in the big toe) and causes swelling and intense pain.
Increased serum urate levels, which are also associated with high blood
pressure, diabetes, and several other important conditions, can be
caused by eating food that is rich in chemicals called purines (for
example, liver, dried beans, and port). The body also converts its own
purines into uric acid so genetic variations in the enzymes involved in
purine breakdown can alter serum urate levels, as can variations in the
rate of urate removal from the body by the kidneys. Urinary urate
excretion is controlled by urate transporters, proteins that carry urate
into and out of the kidney cells. Uricosuric drugs, which are used to treat
gout, reduce serum urate levels by inhibiting a urate transporter that
reabsorbs urate from urine.
Why Was This Study Done? Several urate transporters have already
been identified but recently, using an approach called genome-wide
association scanning, scientists found that some genetic variants of a
human gene called SLC2A9 are more common in people with high serum
urate levels than in people with normal levels. SLC2A9 encodes a glucose
transporter (a protein that helps to move the sugar glucose through cell
membranes) and is highly expressed in the kidney’s main urate handling
site. Given these facts, could SLC2A9 (the protein made from SLC2A9) be
a urate transporter as well as a glucose transporter? In this study, the
researchers investigate this possibility and also ask whether genetic
variations in SLC2A9 might be responsible for the association between
serum urate levels and high blood pressure.
What Did the Researchers Do and Find? The researchers first
expressed SLC2A9 in frog eggs, a type of cell that does not have its
own urate transporter. They found that urate rapidly moved into eggs
expressing SLC2A9 but not into control eggs, that SLC2A9 transported
urate about 50 times faster than glucose, and that glucose stimulated
SLC2A9-mediated urate transport. Similarly, overexpression of SLC2A9 in
human embryonic kidney cells more than doubled their urate uptake.
Conversely, when the researchers used a technique called RNA
interference to reduce the expression of mouse SLC2A9 in mouse cells
that normally makes this protein, urate transport was reduced. Next, the
researchers looked at two small parts of SLC2A9 that vary between
individuals (so-called single polynucleotide polymorphisms) in nearly 900
men who had had their serum urate levels and urinary urate excretion
rates measured. They found that certain genetic variations at these two
sites were associated with increased serum urate levels and decreased
urinary urate excretion. Finally, the researchers used a statistical
technique called meta-analysis to look for an association between one
of the SLC2A9 gene variants and blood pressure. In two separate meta-
analyses that together involved more than 20, 000 participants in several
studies, there was no association between this gene variant and blood
pressure.
What Do These Findings Mean? Overall, these findings indicate that
SLCA9 is a high capacity urate transporter and suggest that this protein
plays an important part in controlling serum urate levels. They provide
confirmation that common genetic variants in SLC2A9 affect serum urate
levels to a marked degree, although they do not show exactly which
genetic variant is responsible for increasing serum urate levels. They also
provide important new insights into how the kidneys normally handle
urate and suggest ways in which this essential process may sometimes
go wrong. Thus, these findings could eventually lead to new treatments
for gout and possibly for other diseases that are associated with
increased serum urate levels.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050197.
 The UK National Health Service Direct health encyclopedia provides
detailed information for patients about gout
 MedlinePlus provides links to many sources of information about gout
(in English and Spanish), including ‘‘What is gout?’’, an easy-to-read
guide from the US National Institutes of Arthritis and Musculoskeletal
and Skin Diseases
 Wikipedia also has pages on gout, uric acid, and SCL2A9 (note:
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
 The Arthritis Research Campaign also has information on gout
PLoS Medicine | www.plosmedicine.org October 2008 | Volume 5 | Issue 10 | e1971523
SLC2A9 Is a Novel Urate Transporter
